

## Special Issue

# Cellular and Metabolic Reprogramming in Cancer

### Message from the Guest Editors

Cancer is a heterogeneous disease caused by genetic and epigenetic changes conferring characteristic properties to cancer cells. Cancer cells have the capability to modify and reprogram their cellular metabolism in order to support biomass production and proliferation. Cellular and metabolic reprogramming can occur in response to both intracellular and extracellular signals, including growth factors and cytokines, ECM remodelling and chronic inflammation. Cellular and metabolic reprogramming contributes to acquired drug resistance to anti-cancer agents, significantly limiting patient survival. The purpose of this Special Issue is to focus on cutting edge research and cover advances on cellular and metabolic reprogramming in malignancies, including cancer stem cells and differentiation, extracellular matrix remodeling, metabolic switches, and anticancer strategies, their therapeutic potential, benefits, possible complications, and pitfalls of such approaches. We invite authors to submit original and novel review articles on basic and translational research.

- cancer
- stem cells
- differentiation
- cellular reprogramming
- metabolic reprogramming/adaptation

### Guest Editors

Dr. Evangelos Kolettas

Dr. Maria Georgiadou

Dr. Eugenia Roupakia

### Deadline for manuscript submissions

closed (31 December 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/151334](https://mdpi.com/si/151334)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).